GeneralConnection.com ➔ Dictionary
Dictionary Search

factor ix

Synonyms

Noun

1. Christmas factor

2. factor IX, coagulation factor, clotting factor

Usage
Repeated Altuviiio dosing doesn’t boost risk of blood clots in mice - Hemophilia News Today
Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials - Nature
Etranacogene Dezaparvovec May Yield Long-Term Factor IX Expression Improvement in Hemophilia B - Hematology Advisor
Single-Dose Gene Therapy Shows Promising Safety, Efficacy, and Patient-Reported Outcomes in Hemophilia B - Docwire News
Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B - The New England Journal of Medicine
Angela Dugalic is UCLA’s X-factor - The IX Sports
EAHAD 2026: Nine-Year Outcomes of Gene Therapy - EMJ
Tailored collagen binding of albumin-fused hyperactive coagulation factor IX dictates in vivo distribution and functional properties - Nature
Explainer: Why Is Hemophilia B Called Christmas Disease? - Global Biotechnology Company
Advances in hemophilia, sickle cell disease, and thalassemia - Penn Medicine
Hemophilia B Gene Therapy Continues to Reduce Bleeding - Medscape
AAV gene therapy shows durable benefit in hemophilia B - 2 Minute Medicine
Optimization of hemophilia B treatment via population PK modeling of rIX-FP, including a 3-week regimen - Frontiers
ASH: CSL proves efficacy of hemophilia B gene therapy Hemgenix holds up after 5 years - Fierce Pharma
Sanofi’s hemophilia B therapy Alprolix approved for 6-month room-temperature storage - koreabiomed.com
Gene Therapy Supply Runs Out, Company Warns of Treatment Delays - MedPage Today
Clinical Scenarios in Hospitalized Patients With Hemophilia - Cureus
New data suggest gene therapy may reach more hemophilia B patients - Hemophilia News Today
How Gene Therapy Is Transforming Hemophilia B Treatment - Docwire News
How durable is gene therapy for haemophilia B? - Nature
Biogen Idec to Present Data from Hematology Programs, Including ELOCTATE™ and ALPROLIX® at ASH Annual Meeting - Biogen
Factor VIII and Factor IX | Community Counts - Centers for Disease Control and Prevention | CDC (.gov)
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant - The New England Journal of Medicine
Coagulation factor IX analysis in bioreactor cell culture supernatant predicts quality of the purified product - Nature
First subject dosed in Be Biopharma’s trial of haemophilia B therapy - Clinical Trials Arena
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B - The New England Journal of Medicine
The National “New Methods” Decision Forum in Norway recommends CSL’s gene therapy HEMGENIX® for adults with severe or moderately severe haemophilia B without a history of Factor IX inhibitors - Mynewsdesk
Effects of codon optimization on coagulation factor IX translation and structure: Implications for protein and gene therapies - Nature
Successful management with regular factor IX replacement during pregnancy in a hemophilia B carrier: A case report - Wiley
Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B - The New England Journal of Medicine
Systemic delivery of factor IX messenger RNA for protein replacement therapy - PNAS
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B - The New England Journal of Medicine
Genome wide CRISPR/Cas9 screen identifies the coagulation factor IX (F9) as a regulator of senescence - Nature
A novel snake venom C-type lectin-like protein modulates blood coagulation by targeting von Willebrand factor and coagulation factor IX - Nature
X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua) - The New England Journal of Medicine
HTC Population Profile Patient Characteristics - Centers for Disease Control and Prevention | CDC (.gov)
Plasma factor IX: The tip of the iceberg? - Sidonio - 2021 - Haemophilia - Wiley Online Library
Plasma Kallikrein Contributes to Coagulation in the Absence of Factor XI by Activating Factor IX - American Heart Association Journals
Field Study Highlights Differences in Factor IX Variant Lab Results - AJMC
PBPK modeling of recombinant factor IX Fc fusion protein (rFIXFc) and rFIX to characterize the binding to type 4 collagen in the extravascular space - Wiley
First gene therapy to treat haemophilia B - European Medicines Agency (EMA)
Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab - American Heart Association Journals
Etranacogene Dezaparvovec Shows Durable Activity and Reduced Consumption of Factor IX in Hemophilia B After 3 Years - CGTLive®
This gene therapy costs $5 million a dose. Is it worth the price? - SMH.com.au
A coagulation factor moonlights in the heart - Science | AAAS
UC San Diego Health First to Offer Novel Gene Therapy for Hemophilia B - UC San Diego Health
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial - Applied Clinical Trials Online
FDA Accepts Biogen Idec’s Biologics License Application for First Long-Lasting Factor IX Therapy for Hemophilia B - Biogen
Switching From Standard to Extended Half-Life Coagulation Factor Replacement in Haemophilia: Clinical Outcomes and Costs of Care in Finland - Wiley Online Library
Regeneron and Intellia Therapeutics Expand Collaboration to Develop CRISPR/Cas9-Based Treatments - Intellia Therapeutics
SRY-Box transcription factor 9 triggers YAP nuclear entry via direct interaction in tumors - Nature
Phase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B - The New England Journal of Medicine
Etranacogene dezaparvovec gene therapy reduces bleeding in severe hemophilia B - 2 Minute Medicine
Intellia opts out of hemophilia B gene editing work with Regeneron - Fierce Biotech
Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies - Wiley Online Library
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A - The New England Journal of Medicine
Glucocorticoids increase adiposity by stimulating Krüppel-like factor 9 expression in macrophages - Nature
Low-dose AAVS3 gene therapy is efficacious for treating patients with hemophilia B - 2 Minute Medicine
Sustained correction of bleeding disorder in hemophilia B mice by gene therapy - PNAS
Anticoagulant Protein S Targets the Factor IXa Heparin-Binding Exosite to Prevent Thrombosis - American Heart Association Journals
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response - Nature
Evaluation of a New Concentrate for the Treatment of Factor IX Deficiency - The New England Journal of Medicine
Coagulation factors VII, IX and X are effective antibacterial proteins against drug-resistant Gram-negative bacteria - Nature
Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector - Nature
Association Between Hepatic Triglyceride Content and Coagulation Factors: - American Heart Association Journals
High Adherence, Excellent Outcomes Seen With EHL Factor VIII and IX Concentrates in Hemophilia - Hematology Advisor
Loss of Krüppel-like factor 9 deregulates both physiological gene expression and development - Nature
Crystal structure of an anticoagulant protein in complex with the Gla domain of factor X - PNAS
Sustained Clinical Benefit of AAV Gene Therapy in Severe Hemophilia B - The New England Journal of Medicine
Personal Story: Carrie - Centers for Disease Control and Prevention | CDC (.gov)
Effective Blood Clotting Treatment:Pharmacogenomic Studies of ADAMTS13 - fda.gov
Fidanacogene Elaparvovec Shows Strong Results in Open-Label Phase 3 Study - AJMC
Hemophilia B gene therapy demonstrates long-term success - St. Jude Children's Research Hospital
Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial - The Lancet
A genetic analysis of 23 Chinese patients with hemophilia B - Nature
Single-dose gene therapy is potentially life-changing for adults with hemophilia B - Penn Medicine
Hemophilia B Gene Therapy Shows Promise as Long-Term Treatment - Docwire News
New Biogen Hemophilia Data At ISTH Congress to Highlight Extension Study Outcomes and Pediatric Use - Biogen
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors - The New England Journal of Medicine
Hemophilia B Gene Therapy Sustains Efficacy Over a Decade Later - MedPage Today
Factor IX product launched in US - MDEdge
The Prevalence of Proteolytic Antibodies against Factor VIII in Hemophilia A - The New England Journal of Medicine
FDA Approves Second Gene Therapy for Hemophilia B - Medscape
Is Hemophilia a Nosologic Entity? - ScienceDirect.com
Fibroblast Growth Factor 9 is expressed by activated hepatic stellate cells and promotes progression of hepatocellular carcinoma - Nature
Hemophilia B Gene Therapy Shows Promise in Clinical Trial - Genetic Engineering and Biotechnology News
World Haemophilia Day on April 17 - Manorama Yearbook
Phase III BENEGENE-2 Trial Shows Beqvez Significantly Reduces Bleeding in Hemophilia B - Applied Clinical Trials Online
Anticoagulant Protein S Targets the Factor IXa Heparin-Binding Exosite to Prevent Thrombosis - American Heart Association Journals
Catalyst’s FIX Gene Therapy More Effective Than Padua in Early Study - Hemophilia News Today
Gene Therapy AMT-061 Provides Greater Factor IX Activity to Possibly Prevent Joint Disease, Study Reports - Hemophilia News Today
uniQure announces FDA approval of first gene therapy for adults with hemophilia B - uniqure.gcs-web.com
Researchers welcome $3.5-million haemophilia gene therapy — but questions remain - Nature
Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A - The New England Journal of Medicine
Lipid nanoparticles deliver messenger RNA for hemophilia B protein replacement therapy [PreClinical] - 2 Minute Medicine
Krüppel-like factor 9 is a circadian transcription factor in human epidermis that controls proliferation of keratinocytes - PNAS
Expert Q&A: The Current State of Gene Therapy for Hemophilia - Hematology Advisor
One dose of gene therapy gives years of relief from blood disorder - Nature
FDA Approves Gene Tx for Hemophilia B – Beqvez - Anton Health
FDA OKs Second Gene Therapy for Hemophilia B - MedPage Today
Foreign Language Equivalents
Foreign Language Equivalents of 'factor ix'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
dactor ix,   factor ux,   factr ix,   ffactor ix,   factor ix,   factor i,   actor ix,   facor ix,   fcator ix,   factor ic,   afctor ix,   factor iz,   faactor ix,   faxtor ix,   factor ox,   factir ix,   factoor ix,   factro ix,   factorr ix,   facto rix,   gactor ix,   factor xi,   facotr ix,   factorix,   factpr ix,   factor x,   fatcor ix,   factor ixx,   fctor ix,   factot ix,   facyor ix,   fsctor ix,   facttor ix,   factori x,   facter ix,   facctor ix,   factor iix,   facror ix,   factoe ix,   fator ix,   facto ix,   favtor ix
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z